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Abstract: 
Cognitive Deficits in Euthymic Patients with Bipolar Disorder: State or Trait Marker?  
Cognitive deficits have been demonstrated in people in the euthymic phase of bipolar 
disorder. This cross-sectional study compared euthymic bipolar disorder patients 
(N=30)  with never psychiatrically ill controls (N=30) on a neuropsychological test battery 
containing tasks of executive function, the Wisconsin Card Sorting Test (WCST), attention 
and working memory, Digits Forward and Backward, and speed of information processing, 
Digit Symbol. Scores on the Mini Mental State Examination (MMSE) and Vocabulary Test 
did not differ between the groups. The bipolar group were significantly impaired compared to 
controls on various indices of executive function on the Wisconsin Card Sort Test and on the 
Digit tests. The impaired performance on the Digit tests, but not the WCST, was significantly 
associated with medication status, notably prescribed benzodiazepines. There was no 
significant effect of severity or course of illness on performance. The findings support the 
hypothesis that impairments in executive function are present between illness episodes in 
bipolar disorder, and so are not simply state markers.  
Key words: Bipolar disorder, cognition, executive function, mania, depression 
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INTRODUCTION 
Patients with Bipolar Disorder present with cognitive deficits, both during affective episodes 
and euthymic periods. The exact nature of cognitive deficits has been debated; some studies 
have suggested generalised deficits (Coffman et al., 1990; Johnstone et al., 1985; Kessing 
1998; Tham et al., 1997), while others have suggested specific deficits in executive functions 
(Ferrier et al 1999; Rubinsztein et al 2000) . Systematic review and meta analysis have also 
given diverse results. A systematic review by Tsitsipa et al (2015) concluded that the 
neurocognitive deficit in bipolar disorder encompasses almost all neurocognitive domains. 
They suggested that one reason for this could be the heterogeneity of the bipolar group. The 
authors also discuss that there may be a continuum starting from those patients who might not 
differ from healthy controls to those who do not differ from patients with schizophrenia. 
Similar pattern of different cluster of bipolar patients with varying cognitive impairment is 
reported by Roux et al (2017). The authors in a cross sectional study on euthymic patients 
with bipolar disorder identified four distinct cognitive clusters. Two of the clusters had 
average global cognitive performance (with either high or low verbal memory) while the 
other two clusters had either above or below average global cognitive performance. In 
contrast to the more generalised deficits found by Tsitsipa et al (2015), a meta-analysis by 
Torres et al (2007) found that compared to a healthy control group, euthymic bipolar patients 
had specific deficits in attention, processing speed, executive function along with deficits in 
episodic memory.  Bostock et al (2017) in their systematic review of cognitive functions in 
euthymic patients of bipolar disorder also reported specific impairments in cognitive domains 
of executive functions, attention span and verbal memory.  
The origin and course of cognitive deficits remains unclear. It’s possible that the cognitive 
deficits in bipolar disorder may be predominantly neurodevelopmental in nature and 
represent a core primary characteristic of the illness which is evident in first-episode bipolar 
patients and do not progressively worsen in most patients (Bora et al., 2015; Bora et al., 
2017; Samamé et al., 2014). Other reviews have suggested that cognitive functions worsen 
with illness progression (Robinson et al., 2006; Cardoso et al., 2015). The possibility of 
kindling secondary to neurological damage caused by recurrent episodes of bipolar illness 
has been hypothesized  (Kessing et al., 2005). There is a suggestion that this may be 
manifested through cognitive deficits. It is therefore, still not clear whether the cognitive 
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deficits represent a neurodevelopmental trait of Bipolar Disorder or are secondary to 
psychopathology that develops after the onset of mood state 
 
We carried out this study to add to the existing evidence on the nature and extent of these 
cognitive deficits as they can have significant and enduring impact on functioning of the 
individuals affected by bipolar disorder. We tried to address some of the shortcomings of 
previous studies by having stringent criteria of euthymia and trying to control for the effect of 
medications and course of illness.  
 
 
METHODS 
Participants 
This cross-sectional study compared adults in the euthymic phase of bipolar disorder 
with never-psychiatrically ill controls. The patient sample was recruited from consecutive 
patients attending for psychiatric follow-up consultations at King George’s Medical 
University, Lucknow, India. The control participants were recruited from the spouses and 
friends of patients.  The patients and control participants were not matched individually for 
their socio-demographic characteristics but an effort was made to match the two groups 
overall. However, recruitment of the control group participants from spouse and friends 
ensured an overall match between the two groups on sociodemographic factors such as age, 
sex, education, socio-economic status and life style factors.  
 
Inclusion and Exclusion Criteria 
 
Cases were diagnosed, by a Professor of Psychiatry, as having Bipolar disorder, in euthymic 
state for at least 1 month (American Psychiatric Association DSM IV, 1994). For inclusion in 
the study, cases were required to have had at least 2 mood episodes in the previous 5 years, 
minimum 8 years of education and be aged between 20 and 50 years. Patients were excluded 
if they had any comorbid diagnosis, had electro convulsive treatment (ECT) in the last 6 
months, or were experiencing significant side effects on the prescribed medicines. Controls 
were excluded if they had any history of psychiatric illness or a family history of psychiatric 
illness in a first-degree biological relative. Both cases and controls were excluded if there was 
history suggestive of other disorders which can cause cognitive impairment (such as, 
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neurological or cerebrovascular disorder), had a history of recent psychoactive substance use 
or a history of harmful use or dependence (except tobacco), they were not able to complete 
the assessment due to any medical problem or if they had a score of more than 7 on Hamilton 
Rating Scale for Depression (HRSD) or Young Mania Rating Scale (YMRS).  
Procedure 
All subjects gave informed consent. A semi-structured proforma containing a detailed 
psychiatric interview was used to elicit information from patients and controls.  A detailed 
physical and mental state examination was done for all the patients and controls. Side effects 
of medicines were documented using the semi-structured proforma. History of past episodes 
was confirmed using the hospital records, where available. It was ensured that if the patients 
were prescribed benzodiazepine medications, they had not taken it on the day of evaluation. 
Assessments following diagnosis were done by one of the authors, who was a resident doctor 
in Psychiatry at the time of the study and was not blind to the diagnosis of the patient. All the 
participants completed a series of neuropsychological tests administered individually. The 
whole assessment was carried out on the same day when the mood rating scales were 
administered (the YMRS and HRSD) to ensure that we had a current measure of mood. 
Approval for the study was given by the ethics committee of King George’s Medical 
University, Lucknow, India.  
 
Measures 
Following neuropsychological tests were administered to each participant.  
Wisconsin Card Sorting Test 
Wisconsin Card Sorting Test (WCST) (Revised and expanded version, Heaton et al., 1993) is 
a measure of executive function requiring the ability to develop and maintain an appropriate 
problem-solving strategy, and to shift attentional set as the rules are covertly changed.14 
 
Wechsler Adult Intelligence Scale Subtests (Wechsler, 1997)  
We used the Digit Forwards test, which assesses immediate verbal memory span, the Digit 
Backwards, which assesses both immediate verbal memory span and the ability to manipulate 
the information in verbal working memory, and the Digit Symbol, which assesses speed of 
information processing and attention. 
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The Mini-Mental State Examination  (Folstein et al., 1975)   
The Mini-Mental State Examination is a test of a broad array of cognitive functions including 
orientation, memory, and language. It was used to identify and exclude potential participants 
with early onset dementia. 
Vocabulary Test (Stanford-Binet Intelligence Scale Subtest-Form L -M1960, Hindi 
Adaptation by Kulshrestha, 1971). The Vocabulary test was used in our study to get an 
approximate measure of premorbid intelligence. 
Statistical Analysis 
Clinical and socio-demographic data were compared using student t-tests and Chi square 
analyses. Neuropsychological data were analyzed using t-tests. Significance level was kept at 
.05 for all the analyses. To control for type 1 error due to multiple comparisons, the p value 
was Bonferroni corrected and the corrected p values were considered significant at .005 level 
(.05/8 neuropsychological variables). All data were analyzed with SPSS for windows 16. 
RESULTS 
Out of the 69 patients screened, 34 met criteria for inclusion in the study. Two of them did 
not turn up for the assessment while another 2 were subsequently excluded as their HRSD 
score was more than 7 at the time of detailed assessment. Thirty patients were therefore 
included in the study.  Out of the 74 controls screened, 30 were included in the study. The 
patient sample in our study was 90% male (27/30). We did not make any effort to balance the 
gender ratio and consecutive patients who met selection criteria were included. The 
predominantly male composition of the patient group in this study may reflect the trend of 
patients with bipolar disorders attending the psychiatry outpatient department at the hospital 
where the study was done.  
The patient and control group were comparable on socio-demographic characteristics of age, 
gender and number of years of education they had (table 1). Their premorbid intelligence 
assessed through vocabulary subtest of WAIS was comparable and they had similar scores on 
their YMRS and the HRSD scores (all p>0.05; see table 1). The patients’ drug status was the 
same for at least the previous 2 months. No patient included in the study was diagnosed to be 
having any other co-morbid psychiatric disorder at the time of assessment. 
Insert Table 1 here 
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On the MMSE, which assesses overall general cognitive ability, the bipolar affective disorder 
(BPAD) patient group did not significantly differ from the control group (p=.094). The 
patient group performed significantly worse on measures of information processing (digit 
forward and digit symbol substitution tests) and working memory test as assessed by digit 
backward test  (all ps<.001). Furthermore, the BPAD patients were significantly impaired on 
various parameters of executive functions as assessed by the WCST: the patients group had 
poor conceptual ability, completed lesser number of categories, committed more errors, and 
made more perseverative responses and perseverative errors (all ps <.001, significant after 
Bonferroni correction). The patient group also made more non-perseverative errors but this 
difference was not significant (p=.043, not significant after Bonferroni correction). These 
results are shown in table 2.  
Insert Table 2 here.  
We were interested in understanding if the observed cognitive deficits could be explained by 
the medications that 25 out of the 30 patients in our study were taking. We, therefore, divided 
them into 2 subgroups based on their medication status.  Those patients who were on 
medications implicated for causing cognitive side effects were placed in “Patient Meds A” 
group (n=13) while the “Patient Meds B” group (n=17) had either drug free patients (n=5) or 
those taking medications unlikely to cause cognitive side effects (see tables 3).  
Insert Table 3 here 
None of the patients had troublesome side effects and the dosages were well within 
therapeutic range. One way analysis of variance (ANOVA) analyses were carried out 
individually on each of the variables with the groups (Patient Meds A, Patient Meds B, 
Control) as between subject factor.  Significant group effect was followed up by post hoc 
Tukey HSD test. To control for the type I error Bonferroni corrected significance level was 
.006 (.05/8 ANOVAS). The ANOVA analyses showed that the three groups were 
significantly different on the Digit Forward test, F(2,57)=9.57, p=.001, ɳ2= .251 and on the 
Digit Symbol test , F(2,57)=13.48, p=.001, ɳ2= .321.  Post hoc test revealed that the “Patient 
Meds A” group had significantly worse performance on the Digit Forward and Digit Symbol 
tests compared to the control group (p=.001 & p=.001 respectively) and “Patient Meds B” 
group (p=.024 & p=.002 respectively). However, Patient Meds B” group did not differ from 
the control group on the Digit Forward or Digit Symbol tests (p=.298 & p=.449 respectively). 
On the Digit Backward test the ANOVA analysis showed a significant main effect of groups, 
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F(2,57)=9.24, p=.001, ɳ2= .245. Post-hoc test showed that the “Patient Meds A” group had 
significantly worse performance compared to the control group only (p=.001). “Patient Meds 
B” group were marginally more impaired than the control group (p=.062) but did not differ 
significantly from the “Patient Meds A” group (p=.157). On the measures of the WCST, the 
ANOVA analyses revealed a significant main effect for groups on % preservative error 
scores F(2,57)=5.66, p=.006, ɳ2= .166, where both the “Patient Meds A” and “Patient Meds 
B” groups had worse performance than the control group (p=.032 & p=.015 respectively) but 
they  did not differ significantly from each other (p=.996). Similarly, a significant main effect 
for groups was observed on % conceptual level response F(2,57)=7.60, p=.001, ɳ2= .217. The 
Post hoc test revealed that the both “Patient Meds A” and “Patient Meds B” groups had 
significantly worse performance compared to the control group (p=.005 & p=.007 
respectively) while they  did not differ significantly from each other (p=.937). This trend of 
results continued on the number of categories completed scores where a significant main 
effect of groups was found F(2,57)=8.12, p=.001, ɳ2= .228. The Post hoc test revealed that 
both the “Patient Meds A” and “Patient Meds B” groups had significantly worse performance 
compared to the control group (p=.005 & p=.004 respectively) and again they  did not differ 
significantly from each other (p=.983). However, on the % non-perseverative error scores and 
the % preservative response the three groups did not differ significantly, F(2,57)=2.05, 
p=.139, ɳ2= .069 and F(2,57)=4.31, p=.018, ɳ2= .136 respectively. A summary pattern of this 
result is presented in table 4.  
Insert table 4 here 
We were also interested in understanding if those patients who were judged to have a less 
severe course were more impaired on neuropsychological functions compared to those who 
were judged to have a more severe course. Less severe course (n=15) was defined as no more 
than 2 major affective episodes in the last 5 years with recovery within 12 weeks of referral 
for specialist treatment. More severe course (n=15) was defined as at least 3 major affective 
episodes in the last 3 years or 1 year of unremitting illness in the last 3 years. Similar criteria 
were used in a study done by Ferrier et al (1999) to define the course of illness. The basic 
sociodemographic characteristics did not differ significantly between the two patient groups 
(all ps>.28). The two groups performed similarly (all ps>.29) on measures of information 
processing, working memory, and executive functions (table 5). 
Insert Table 5 here 
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DISCUSSION: 
The study investigated if euthymic bipolar disorder patients show cognitive deficits on tests 
of executive functions, speed of information processing and attention. Compared to a 
matched healthy control group, the patients had deficits in the areas of immediate verbal 
memory span (the Digit Forwards and Backwards tests), ability to manipulate the information 
in verbal working memory (the Digit Backwards test), speed of information processing and 
attention (the Digit Symbol test) and various aspects of executive functions (the WCST).  Our 
results are consistent with other studies; a meta-analysis by Torres et al (2007) found that 
compared to a healthy control group, euthymic bipolar patients had deficits in attention, 
processing speed, executive function along with deficits in episodic memory (Torres et al., 
2007). More recent studies (Varbie et al., 2015) also supported similar findings.  
 
It has been a lingering question in research in mood disorders if the cognitive deficits are a 
state marker or trait marker and /or if the cognitive deficits are secondary to the effect of 
medication. To investigate if the cognitive deficits present in the euthymic bipolar patients 
are affected by the medication status of the patients we divided the patients into further two 
groups. “Patient Meds A” group  included those who were on medications typically known to 
cause cognitive impairment and “Patient Meds B” group  included those who were not on any 
medication or on medication not known to cause significant cognitive impairment. Eight out 
of 13 patients in “Patient Meds A” group were on benzodiazepines, which can affect 
performance on cognitive tests and cause drowsiness. It was, therefore, ensured that they had 
not taken benzodiazepine medication on the day of evaluation. The findings showed that on 
measures of executive functions as measured by the WCST, the two groups of patients did 
not differ from each other. Both groups of patients were significantly impaired on the 
measures of WCST as compared to the control group. However, the “Patient Meds A” group 
patients were more severely impaired on tests of immediate verbal memory span (the Digit 
Forwards and Backwards tests), ability to manipulate the information in verbal working 
memory (the Digit Backwards test), speed of information processing and attention (the Digit 
Symbol test). The results were statistically significant on the Digits forward and Digits 
symbol tests. However, the difference between the two groups was not large enough to reach 
significance levels on the Digits backward test. The “Patient Meds A” group had comparable 
performance to the controls on these tests. These findings highlight the effect of medications 
on certain aspects of cognitive functioning in BPAD patients, especially speed of information 
 10 
processing and immediate memory span. A recent meta-analysis concluded that 
benzodiazepines negatively affect performance on a number of cognitive domains including 
that of recent memory, processing speed, visuoconstruction, divided attention, working 
memory, and sustained attention (Crowe et al., 2017). These negative effects were present 
even in those who had withdrawn from benzodiazepines. Our findings hence suggest that 
executive function deficits as measured by the WCST are not secondary to effects of 
medications while other deficits could be due to the effects of medication. A number of 
reviews and meta-analyses have consistently shown that the residual cognitive deficits during 
euthymia are specific to executive functions (Torres et al., 2007; Bostock et al., 2017). Torres 
et al (2007) also suggested that the effects of medication do not fully account for the 
cognitive deficits observed in bipolar patients. This has important clinical implications as 
some cognitive deficits can be avoided by being judicious about the use of medications. Use 
of benzodiazepines and anticholinergics should be best avoided, where possible.  
 
The wide variety of findings from generalised to specific cognitive deficits in euthymic 
patients of bipolar disorder may arise owing to several factors, such as patient selection and 
medication use. In the current study we ensured that our patients were in complete remission 
and their scores on YMRS and HRSD were not different from the controls and were below 
threshold for mood related states. A recent review (Tsitsipa et al., 2015) concluded that the 
neurocognitive deficit in bipolar disorder encompasses almost all neurocognitive domains. 
However, they suggested that only executive function and verbal memory deficit may be core 
deficits while other impairments probably reflect the heterogeneous nature of the subjects in 
various studies including symptomatology, the type and severity of Bipolar Disorder, 
medication status etc. We used stringent criteria for the diagnosis of Bipolar with at least 2 or 
more episodes of mania in the last 5 years, as evidenced by their clinical records. This 
ensured the validity and stability of the diagnosis. The diagnosis was made by an experienced 
psychiatrist (a Professor of Psychiatry) and further substantiated by using a semi-structured 
interview pro forma. The patients had to be in remission for at least 1 month to qualify to be 
in a euthymic phase. 
 
The group which had a relatively less severe course had similar cognitive performance to the 
group with the more severe course. Our findings are supported by Ferrier et al (1999) who 
also found no difference between the good and poor outcome patients, using similar criteria 
as in our study. These findings lend support to the hypothesis that the specific cognitive 
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deficits observed in the euthymic period may actually be a trait marker of bipolar disorder, 
which do not necessarily worsen with worsening clinical outcome. Our findings are in 
accordance with recent meta-analyses (Bora et al., 2015; Bora et al., 2017) which have 
suggested that neurocognitive deficits are evident in first-episode bipolar patients and don’t 
progressively worsen in most patients. A recent meta-analysis (Bortolato et al., 2015) 
suggested that a subgroup of individuals with bipolar disorder may even have significant 
impairment that even predate the onset of bipolar disorder suggesting the role of 
neurodevelopmental factors in bipolar disorder. However, the other hypothesis that cognitive 
functions worsen with illness progression (Robinson et al., 2006; Cardoso et al., 2015) cannot 
be completely ruled out as yet.  
 
It has been demonstrated that cognitive deficits are a vulnerability factor for affective illness 
in a community sample of adolescents (Owens et al 2012). It is possible that cognitive 
deficits may be present before the illness onset and interact with other vulnerability factors to 
cause illness.  This can only be studied in longitudinal studies where a high-risk cohort group 
is recruited before the onset of illness.  
 
Strengths  
The main strength of our study is the stringent definition of euthymia and no difference in 
HDRS and YMRS scores between the patients and controls. The control group had no family 
or personal psychiatric history.  
Limitations 
The diagnosis in all cases was made by an experienced psychiatrist (a Professor of 
Psychiatry) but a structured diagnostic tool was not used. Our sample size was small and a 
majority of our patients were on medication, hence the confounding effect of medication 
cannot be completely ruled out. We tried to address this by doing post hoc analyses, but due 
to the small sample size, results need to be interpreted with caution. Another limitation of our 
study is that the sample consisted of 90% males. Though this reflects the pattern of 
attendance for patients with biplolar disorders in the period when the study was conducted, 
this limits the generalizability of the study.  
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CONCLUSION  
Our study demonstrates that specific executive function deficits exist in patients in the 
euthymic phase of  bipolar disorder. These deficits can cause significant impairment in 
daily life of individuals with BPAD. Therefore, there is a need to develop rehabilitative and 
treatment models aimed at addressing/improving these cognitive deficits to achieve better 
functioning on recovery. 
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Table 1: Comparisons of socio-demographic characteristics, mood level 
vocabulary test and MMSE score of the patient and control groups. 
Variables  Patients (Mean + SD) 
(N=30) 
Controls (Mean + SD) 
(N=30)  
  ‘t’    ‘x’    ‘p’ 
Age in years  34.27+8.29 34.63+8.08 1.70  0.865 
Sex - N(%) 
    Male  
    Female 
 
27(90%) 
3(10.0%) 
 
26(86.67%) 
4(13.33%) 
 
 
 
0.16 
 
0.69 
Mean years of education  10.27+2.80 10.40+2.87 0.178  .860 
Young Mania Rating Scale(YMRS) 0.90+1.06 0.94+1.03 0.148  .883 
Hamilton Rating Scale for 
Depression (HRSD) 
1.97+1.81 1.83+1.95 0.288  .774 
Vocabulary test  19.67+8.27 18.63+8.03 0.494  .623 
Mini Mental State Examination 
(MMSE) 
27.53+1.53 28.23+1.65 1.70   0.447 
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Table 2:  Comparison of neuropsychological functions between the control and BPAD 
patient groups.  
Neuropsychological 
Variables 
Patients 
(Mean+SD) 
(N=30) 
Control 
(Mean+SD) 
(N=30) 
t 
values 
p 
values 
d 95% CI 
Digits Forward 5.13+1.25 6.07+0.94 3.26 .002  0.865 -1.51 to 
-0.368  
Digits Backward  3.30+0.79 4.07+0.78 3.76 .001  0.998  -1.17 to 
-0.364  
Digit Symbol 27.00+7.31 34.33+9.25 3.41 .001  0.879  -11.6 to 
-3.02  
%Perseverative 
Response 
39.67+13.81 26.93+18.69 3.00 .004 0.775 4.25 to 
21.2  
%Perseverative Error 33.47+10.27 22.77+13.87 3.40 .001 0.877 4.39 to 
17.0  
% Non-Perseverative 
Errors 
17.13+8.63 13.10+6.33 2.06 .043 0.532 0.119 to 
7.94  
%Conceptual Level 
Response 
35.33+12.35 53.07+21.27 3.95 .001 1.02 -26.7 to 
-8.75  
No. of categories 
completed 
2.83+1.53 4.57+1.72 4.13 .001 1.07 -2.58 to 
-0.899  
d=Cohen d (difference in mean divided by common standard deviation); CI= Confidence 
interval ; bold p values indicate significant after Bonferroni correction. 
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Table 3: Break-Up of Patient Meds A (n=13) and Patients Meds B (n=17) group of patients based on 
their medication status.  
 Number of 
patients  
Duration of current 
treatment in months 
(mean+SD) 
Medications  
  
Patient 
Meds A 
4 19.38+10.98 Lithium alone 
2 18.24+6.02 Lithium with benzodiazepine 
3 9.48+3.08 Valproate with benzodiazepine 
2 10.38+3.02 Carbamazepine with benzodiazepine 
1 9.84 Chlorpromazine with Clozapine and 
Trihexyphenidyl  
1 10.38 Valproate with Carbamazepine and 
lorazepam  
Patient 
Meds B 
4 10.48+8.54 Carbamazepine alone 
3 19.08+6.08 Valproate alone 
3 12.05+6.82 Valproate with Atypical Antipsychotics 
2 15.02+5.33 Carbamazepine with Atypical Antipsychotics  
5 2.4+2.07 Drug free 
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Table 4: Summary results of the control, on medications likely to affect cognition (Patient 
Meds A) and on medications unlikely to affect cognition and those without medication 
(Patient Meds B) patient groups (divided on basis of medication status) on 
neuropsychological functions.  
Neuropsychologic
al Variables 
Control 
(Mean+SD) 
(N=30) 
Group 1 
(N=13) 
Group 2 
(N=17) 
F 
values 
p 
value
s 
Group 
comparisons 
Digits Forward 6.07+0.94 4.54+0.88 5.59+1.33 9.57 .001 MA <C & MB; 
MB=C 
Digits Backward  4.07+0.78 3.00+0.41 3.53+0.94 9.24 .001 MA<C; 
MB~<C; MB= 
M 
Digit Symbol 34.33+9.25 21.31+4.97 31.53+5.63 13.48 .001 MA <C & MB; 
MB=C 
%Perseverative 
Response 
26.93+18.69 39.38+16.3
9 
39.88+12.00 4.31 .018  
%Perseverative 
Error 
22.77+13.87 33.38+11.8
6 
33.53+9.26 5.66 .006 MB & MA<C; 
MB=M 
% Non-
Perseverative 
Errors 
13.10+6.33 16.62+9.87 17.53+7.84 2.05 .139  
%Conceptual 
Level Response 
53.07+21.27 34.08+14.4
3 
36.29+10.84 7.60 .001 MB & MA<C; 
MB=MA 
No. of categories 
completed 
4.57+1.72 2.77+1.83 2.88+1.32 8.12 .001 MF & MA<C; 
MB=M 
 
MA= Patient Meds A group; MB= Patient Meds B group; C= Control group; bold p values 
indicate significant after Bonferroni correction; ~ marginal significance indicated between 
MF and C on the digit backward test. Group comparisons reported are the significant 
differences observed between the groups following post hoc tests.  
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Table 5: Comparison of performance on neuropsychological test measures between less 
severe and more severe course BPAD patients.  
Neuropsychological 
Variables 
Less severe 
course 
patients 
(Mean+SD) 
(N=15) 
More 
severe 
course 
patients 
(Mean+SD) 
(N=15) 
t values p 
values 
d 95% CI 
Digits Forward 5.13+1.36 5.13+1.19 0.000 1.00 0. 000 -0.660 to 
0.660 
Digits Backward  3.30+0.722 3.27+0.881 0.102 .919 0.037  -0.385 to 
0.445 
Digit Symbol 28.5+6.36 25.5+8.10 1.10 .278 0.404  -0.824 to 
6.704 
%Perseverative 
Response 
51.9+8.75 48.4+13.3 0.851 0.402 0.314 -2.28 to 
9.34  
%Perseverative 
Error 
41.00+13.83 38.3+14.14 0.529 0.601 0.191 -4.56 to 
9.90  
% Non-
Perseverative Errors 
34.7+10.0 32.27+10.73 0.642 0.526 0.231 -2.96 to 
7.76 
%Conceptual Level 
Response 
34.5+10.5 36.13+14.29 0.356 0.724 -0.127  -8.08 to 
4.88  
No. of categories 
completed 
2.53+1.25 3.13+1.77 1.075 0.29 -0.391  -1.39 to 
0.19 
 
d=Cohen d (difference in mean divided by common standard deviation); CI= Confidence 
interval 
 
 
